Chiome Bioscience Inc. (JP:4583) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chiome Bioscience has entered into an exclusive licensing agreement with Asahi Kasei Pharma for the development and commercialization of its humanized anti-CX3CR1 antibody, PFKR. The deal includes upfront payments and potential milestone and royalty earnings, promising significant financial gains for Chiome. This partnership aims to accelerate the antibody’s market presence, enhancing its value and impact in the healthcare industry.
For further insights into JP:4583 stock, check out TipRanks’ Stock Analysis page.